Altimmune reports Q2 2026 results and business update
The company initiated a Phase 3 MASH trial, reported positive AUD trial data, completed ALD trial enrollment, and holds $519 million in cash.
Latest Altimmune News & Updates
See the latest news and media coverage for Altimmune. We track all announcements, press releases, and industry mentions in real time, all in one place.
Late-stage biopharmaceutical company developing therapeutics to treat serious liver disease
altimmune.com- Headquarters
- Gaithersburg, United States
- Founded year
- 1997
- Company type
- Public company
- Number of employees
- 10–90
- Industry
- Pharmaceuticals
Last updated
Latest news about Altimmune
In short: Altimmune advanced pemvidutide to Phase 3 for MASH, reported positive Phase 2 AUD data, raised $281M, and named a new principal accounting officer.
Company announcements
Altimmune hosts Q2 2026 earnings call
The company will discuss financial results on August 12, 2026 via a webcast for investors and stakeholders.
Altimmune initiates PERFORMA Phase 3 trial of pemvidutide
The global registrational study evaluates pemvidutide in MASH patients with moderate to advanced fibrosis, following positive Phase 2b data. Topline data expected in 2029.
Altimmune announces positive RECLAIM Phase 2 trial results
Pemvidutide met its primary endpoint of reducing heavy drinking days and showed favorable tolerability.
Media coverage
"US Stock Thematic Weekly Report": Aging Management and Longevity Medicine — NVO, LLY, ALT
Recently, company executives publicly identified peptide injection products used for skin improvement, anti-aging, athletic recovery, and muscle gain, which have not undergone human clinical trials, as falling under the "untested" category, and advocated for stricter FDA regulation. This signals a clear distancing by major metabolic drug manufacturers from the gray market of biohacking peptides. Altimmune (ALT.US) recently announced Phase 2 results for pemvidutide in alcohol use disorder; in a 24-week trial involving approximately 100 moderate-to-severe patients, nearly two-thirds of subjects dropped two levels on the WHO risky drinking scale, and...
Altimmune's (ALT) Three Liver Trials Move Forward At Once
On August 12, Altimmune (NASDAQ:ALT) reported second quarter results that read less like a routine earnings update and more like a status check on three...
US Altimmune's glucagon/GLP-1 receptor dual agonist significantly improves drinking behavior in phase 2 targeting alcohol use disorder
US Altimmune, a company specializing in the development of new drugs for chronic liver disease, announced on July 28, 2026, that it has met its primary endpoint in a phase 2 clinical trial (RECLAIM trial) targeting alcohol use disorder (AUD) with pemvidutide, a glucagon/glucagon-like peptide-1 (GLP-1) receptor dual agonist...
Altimmune (NASDAQ:ALT): What Does the Latest Update Mean for Trial Execution?
Current company-specific hook: its quarterly update renewed attention on metabolic-disease drug development. The central reader questions concern trial execution and clinical differentiation and cash ...
Never miss news about Altimmune
Track Altimmune and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Altimmune competitors & trending companies
Browse news for competitors to Altimmune and other trending companies.
Ochre
Sobrera
Akero
Clinsearch
LSS
Avance Biosciences
Argus West
Segers
Grale
Atomic Machines
Wallenberg Investments
Apace
scanware
Lightmatter
Haglöfs
Sweco
Skydance
Koronea
Geberit
Express Electrical
The Electric Connection
XTB
Qair
High Voltage Electrical
EarlyBird Electric
Adept
Atlas Ward
Roplan
GB Verkstad
PostNord
Swedavia
Höga Kusten Airport
Logosol